Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8441059 | European Journal of Cancer | 2016 | 14 Pages |
Abstract
Long-term efficacy supports the established non-inferiority of subcutaneous trastuzumab, and its safety profile remains consistent with the known intravenous profile. In each of HannaH's treatment arms, tpCR was associated with improved EFS, adding to evidence that tpCR is associated with clinical benefit in HER2-positive early breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin-Seok Ahn, Bohuslav Melichar, Shin-Cheh Chen, Sung-Bae Kim, Mikhail Lichinitser, Elżbieta StarosÅawska, Georg Kunz, Silvia Falcon, Shou-Tung Chen, Aulde Crepelle-Fléchais, Dominik Heinzmann,